1 ifying the pancreatic cancer as a functional glucagonoma.

2 nesium responsiveness of NIPAL1 in alpha-TC6 glucagonoma cells (a pancreatic alpha-cell line) were si

3 tryptic fragments derived from insulinoma or glucagonoma cells, blocks the immunoprecipitation of bot

4           Recently, we identified Insulinoma-Glucagonoma clone 20 (IG20) that can render cells more s

5 of the thyroid, and 1 each had a gastrinoma, glucagonoma, fibrolamellar cancer, and malignant histioc

6 y diarrhea, hypokalemia-achlorhydria [WDHA], glucagonoma [glucagonoma syndrome], and so forth).

7 rately successful, with minimal evidence for glucagonomas or metastatic spread.

8                                           In glucagonoma patients, amino acid turnover and ureagenesi

9 oss, as reflected by the wasting observed in glucagonoma patients.

10 imens, death-domain adaptor protein Insuloma-Glucagonoma protein 20 (IG20) is consistently aberrantly

11 ypokalemia-achlorhydria [WDHA], glucagonoma [glucagonoma syndrome], and so forth).

12  In patients with glucagon-producing tumors (glucagonomas), the most conspicuous signs are skin lesio